Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri(Dana-Farber Cancer Institute), Bernard Escudier(Institut Gustave Roussy), Thomas Powles(University College London), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Paul N. Mainwaring(Cancer Council Queensland), Brian I. Rini(Cleveland Clinic), Hans J. Hammers(Sidney Kimmel Comprehensive Cancer Center), Frede Donskov(Aarhus University Hospital), Bruce J. Roth(Washington University in St. Louis), Katriina Peltola(Helsinki University Hospital), Jae‐Lyun Lee(Asan Medical Center), Daniel Y.C. Heng(University of Calgary), Manuela Schmidinger(Medical University of Vienna), Neeraj Agarwal(Huntsman Cancer Institute), Cora N. Sternberg(Carlo Forlanini Hospital), David F. McDermott(Beth Israel Deaconess Medical Center), Dana T. Aftab(Exelixis (United States)), Colin Hessel(Exelixis (United States)), Christian Scheffold(Exelixis (United States)), Gisela Schwab(Exelixis (United States)), Thomas E. Hutson(Texas Oncology), Sumanta K. Pal(City Of Hope National Medical Center), Robert J. Motzer(Memorial Sloan Kettering Cancer Center)
Cited by 937Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis